Welcome!

News Feed Item

Legal Updates, Stock Price Movements, Launch of New Products, and Trial Results - Analyst Notes on Teva, Lilly, Allergan, Illumina, and Regeneron

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 4, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Eli Lilly and Co. (NYSE: LLY), Allergan Inc. (NYSE: AGN), Illumina Inc. (NASDAQ: ILMN), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Teva Pharmaceutical Industries Ltd. Analyst Notes 

On March 31, 2014, Teva Pharmaceutical Industries Ltd. (Teva) announced that the U.S. Supreme Court has agreed to hear the Company's appeal in the patent dispute over its multiple sclerosis (RRMS) product, COPAXONE®. Teva's appeal to the Supreme Court challenges a last year's ruling by the U.S. Court of Appeals for the Federal Circuit and seeks to prevent generic versions of the COPAXONE from entering the market till September 2015. The court had upheld some of the COPAXONE patents that expire in May 2014, while invalidating the '808 patent' that is the subject of Teva's now-granted certiorari petition. The development came as a huge relief for Teva's stock (ADR) which jumped 6.86% to $52.84 on the day of the announcement. Analysts believe that if Teva wins the case, it would result into windfall gains for the Company which earns almost 20% of its sales from the drug which is under dispute. The full analyst notes on Teva Pharmaceutical Industries Ltd. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/TEVA/report.pdf

Eli Lilly and Co. Analyst Notes 

On March 31, 2014, Eli Lilly and Co. (Lilly) announced that the U.S. District Court for the Southern District of Indiana has ruled in favor of the Company in relation to the vitamin dosage regimen patent for Alimta® (pemetrexed for injection). According to the Company, the court ruled that the vitamin dosage regimen patent, which provides intellectual property protection for Alimta until 2022, is valid and enforceable. The Company also stated that Alimta's compound patent remains in force through early 2017. The full analyst notes on Eli Lilly and Co. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/LLY/report.pdf

Allergan Inc. Analyst Notes 

On April 1, 2014, Allergan Inc.'s (Allergan) stock ended the trading session at $123.74, down 0.29%, underperforming the S&P 500 Index which gained 0.70% over the same day. Shares in Allergan opened the session at $124.13 and oscillated in the range of $122.98 - $125.35. Over the past three months, the stock has increased 11.40%, outperforming the S&P 500 Index which gained 2.00% during the same time period. The full analyst notes on Allergan Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/AGN/report.pdf

Illumina Inc. Analyst Notes 

On April 2, 2014, Illumina Inc. (Illumina) announced the expansion of its product portfolio by introducing new products that could be used in discovery and translation of genomic variation in blood and tissue associated with cancer. According to the Company, the expansion of portfolio leverages its industry-leading next-generation sequencing (NGS) and microarray scanning systems to deliver sample-to-data solutions for basic and clinical cancer research. The new products launched are: TruSeq® RNA Access Library Prep Kits which offers a reproducible, economical solution for analyzing RNA isolated from formalin-fixed, paraffin-embedded tissues, and other low-quality samples; TruSight™ Myeloid Sequencing Panel that uses expert-curated content to offer accurate, efficient, and cost-effective identification of somatic mutations in myeloid malignancies; New BaseSpace® Core Apps that offers informatics support for the cancer market. Rick Klausner, M.D., Chief Medical Officer of Illumina, said, "The latest additions to our product portfolio address the unique needs of oncology researchers." The full analyst notes on Illumina Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/ILMN/report.pdf

Regeneron Pharmaceuticals Inc. Analyst Notes 

On April 1, 2014, Regeneron Pharmaceuticals Inc. (Regeneron) and Sanofi jointly announced that the first Phase 2 study with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), in Japanese patients reached its primary endpoint. According to the Company, the results indicated that the mean low-density lipoprotein-cholesterol (LDL-C, or bad cholesterol) percentage reduction from baseline to week 12, the primary efficacy endpoint of the study, was significantly greater in patients randomized to receive one of three doses of alirocumab administered every other week (Q2W) -- 150 milligrams (mg), 75 mg, and 50 mg, in combination with statin therapy, compared to patients receiving placebo. George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories, commented, "The results from this trial support the efficacy and safety of alirocumab at a range of doses in Japanese patients." The full analyst notes on Regeneron Pharmaceuticals Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04042014/REGN/report.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES: 

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com/

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
Kubernetes is an open source system for automating deployment, scaling, and management of containerized applications. Kubernetes was originally built by Google, leveraging years of experience with managing container workloads, and is now a Cloud Native Compute Foundation (CNCF) project. Kubernetes has been widely adopted by the community, supported on all major public and private cloud providers, and is gaining rapid adoption in enterprises. However, Kubernetes may seem intimidating and complex ...
"Outscale was founded in 2010, is based in France, is a strategic partner to Dassault Systémes and has done quite a bit of work with divisions of Dassault," explained Jackie Funk, Digital Marketing exec at Outscale, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We focus on SAP workloads because they are among the most powerful but somewhat challenging workloads out there to take into public cloud," explained Swen Conrad, CEO of Ocean9, Inc., in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"DivvyCloud as a company set out to help customers automate solutions to the most common cloud problems," noted Jeremy Snyder, VP of Business Development at DivvyCloud, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We provide IoT solutions. We provide the most compatible solutions for many applications. Our solutions are industry agnostic and also protocol agnostic," explained Richard Han, Head of Sales and Marketing and Engineering at Systena America, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are still a relatively small software house and we are focusing on certain industries like FinTech, med tech, energy and utilities. We help our customers with their digital transformation," noted Piotr Stawinski, Founder and CEO of EARP Integration, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I think DevOps is now a rambunctious teenager – it’s starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We've been engaging with a lot of customers including Panasonic, we've been involved with Cisco and now we're working with the U.S. government - the Department of Homeland Security," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.